ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO031

Kidney Outcomes in Critically Ill Patients With and Without COVID-19

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Tian, Frances, University of Washington, Seattle, Washington, United States
  • Zelnick, Leila R., University of Washington, Seattle, Washington, United States
  • Wurfel, Mark M., University of Washington, Seattle, Washington, United States
  • Bhatraju, Pavan K., University of Washington, Seattle, Washington, United States
  • Kestenbaum, Bryan R., University of Washington, Seattle, Washington, United States

Case series have described high rates of AKI in critically ill persons with covid-19. However, no study has directly compared kidney outcomes in similarly ill persons with and without covid-19 that are contemporaneously enrolled.


We assessed 346 participants from a study of covid-19 in critical illness enrolled from University of Washington from April 2020 to May 2021. Patients in the ICU were recruited if symptoms of lower respiratory tract infection prompted covid testing. 2/3 of the cohort were covid positive; the remaining 1/3 had another cause of respiratory illness and served as controls. We defined major adverse kidney events (MAKE) as doubling of serum creatinine, dialysis, or death during hospitalization. Among 186 patients with available urine samples, we also assessed kidney injury molecule-1 (KIM-1), epidermal growth factor (EGF), and Cr . We used inverse probability of treatment weighting with propensity scores to increase similarity between the comparison groups.


Mean age was 55 years; 64% were male, and mean admission serum Cr was 1.3 ± 1.0 mg/dL. Baseline characteristics, including APACHE III and SOFA scores, were similar between groups after propensity weighting. Among Covid-19 patients the incidence of MAKE was 45% and in non-covid-19 patients was 26%. Covid-19 positivity was associated with a 55% greater incidence of MAKE and each component of MAKE was numerically higher in the covid-19 positive group (figure). The covid positive group had lower urine EGF levels (indexed to urine Cr) over time. Urine KIM-1 levels were similar.


The incidences of clinical kidney outcomes are numerically higher in critically ill patients with covid-19 compared with similarly ill control patients without covid-19. Urinary concentrations of EGF are lower in covid positive patients.